Last reviewed · How we verify
NCT04163263
Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris
Phase 1 trial testing BOS-356 in Moderate to Severe Acne Vulgaris in 66 participants. Completed in 11 November 2020.
11 November 2020
Quick facts
| Lead sponsor | Boston Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 4 November 2019 |
| Primary completion | 11 November 2020 |
| Estimated completion | 11 November 2020 |
| Sites | 7 locations across Canada, United States |
Drugs / interventions tested
- BOS-356 — full drug profile →
- Vehicle
Conditions studied
- Moderate to Severe Acne Vulgaris — all drugs for Moderate to Severe Acne Vulgaris →
Sponsor
Boston Pharmaceuticals — full company profile →
Who can join
Adults 18 to 45, any sex, with Moderate to Severe Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is being conducted to characterize the safety and tolerability of BOS-356 in adult participants with moderate to severe acne vulgaris following 14 days or 28 days of repeated topical application
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04163263
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Moderate to Severe Acne Vulgaris
Currently open trials in the same condition.
- NCT06378983 — Clinical Trial of Microneedle Radiofrequency Combined With Oral Isotretinoin in Moderate to Severe Acne · NA · recruiting
Other Boston Pharmaceuticals trials
Trials by the same sponsor.
- NCT04880031 — A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an · Phase 2 · completed
- NCT04221906 — Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test · Phase 1 · completed
- NCT04514237 — Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS · Phase 1 · completed
- NCT03977155 — Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predomina · Phase 2 · completed
- NCT03960450 — Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04163263 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston Pharmaceuticals
- Last refreshed: 27 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04163263.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing